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This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality 
and hospitalization in chronic heart failure (HF) patients. 
Methods and results  
Of 16 354 patients included in the European Society of Cardiology Heart Failure Long‐Term Registry, 9428 
chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction 
(LVEF) 37%]. Rates of use of guideline‐directed medical therapy (GDMT) were high (angiotensin‐converting 
enzyme inhibitors/angiotensin receptor blockers, beta‐blockers and mineralocorticoid receptor antagonists: 85.7%, 
88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P 
≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1‐year follow‐up. Sex was not an 
independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT 
underutilization. Rates of all‐cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were 
rates of all‐cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All‐
cause mortality and all‐cause hospitalization increased with greater age in both sexes. Sex was not an independent 
predictor of 1‐year all‐cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly 
lower in patients of younger age, compared to patients aged >75 years. 
Conclusions 
There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of 
GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all‐cause 
mortality in patients with LVEF ≤45%. 
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Introduction 
Heart failure (HF) is a growing health concern affecting more than 26 million patients worldwide.
1, 2
 
Despite advances in treatment, it accounts for significant proportions of hospitalization, disability and 
mortality.
3-6
 Chronic HF predominantly affects elderly people; its incidence doubles in men and triples in 
women with each decade after the age of 65 years.
2
 Clinical trials and registries of chronic HF have 
provided conflicting data on age‐ and sex‐related characteristics in terms of their influence on patient 
management and prognosis.
7-12
 Several studies have indicated a better prognosis in female than in male 
patients,
7-9





With respect to HF treatment, a tendency for the underutilization or suboptimal dosing of guideline‐
directed medical therapy (GDMT) in women and elderly patients compared to men and younger patients 
has been shown. Women with HF receive beta‐blockers (BBs) and angiotensin‐converting enzyme 
inhibitors (ACEIs) less frequently, and at lower than recommended dosages, than men.
13-15
 One study has 
suggested a sex‐specific bias in the choice of HF medication in relation to the health care provider's 
specialty (cardiologist vs. non‐cardiologist).16 In addition, suboptimal dosing of ACEIs and BBs has been 
reported in elderly HF patients.
17-19
 These factors may contribute to the reported lesser improvements in 




The reasons for such age‐ and sex‐related discrepancies in the care of HF patients remain unresolved. 
They may reflect sex and age variability in HF pathophysiology, clinical phenotype, comorbidities and 
response to GDMT. Particularly, there is a paucity of data on medium‐ and long‐term management and 
outcomes in relation to patient age and sex in chronic stable HF patients. 
 
Therefore, the present study aimed to assess age‐ and sex‐related differences in HF management, and 
1‐year risk for all‐cause mortality and hospitalization, in 16 354 HF patients from the European Society of 
Cardiology Heart Failure Long‐Term (ESC HF‐LT) Registry. 
Methods 
Study design and participating centres 
The ESC HF‐LT Registry is a prospective, multicentre, multinational, observational database of 
patients with acute and chronic HF.
22
 It involves a total of 133 participating centres across 21 European 
and Mediterranean countries, of which 47% are university centres, 49% are local/regional centres and 4% 
are based in private hospitals. 
Inclusion and exclusion criteria 
From the overall registry population (n = 16 354) enrolled between 2011 and 2016, for the purpose of 
the present analyses, data on ambulatory patients with HF (n = 9428 patients) were selected. Ambulatory 
patients included all outpatients with chronic HF diagnosed according to the clinical judgement of the 
responsible cardiologist at the participating centre.
22 
Further details on the registry protocol have been 
described elsewhere.
22
 The only exclusion criterion was age <18 years. 
 
At inclusion, demographic and clinical data were collected, and details on HF management before and 
after the ambulatory visit were recorded. Patients were followed up in accordance with the standard of 
care at each participating centre. A mandatory 1‐year visit was set up to obtain data on morbidity, 
mortality and treatment (before and after the follow‐up visit). Follow‐up data were available for >95% of 
patients. The registry was approved by local institutional review boards or ethics committees and 
informed consent documents were signed by all participants. To ensure data quality and consistency, 
training meetings were organized for the investigators and data sources were verified by 
EURObservational Research Programme (EORP) monitors in a random sample of 5% of the enrolled 
patients. 
Statistical analysis 
Descriptive analyses were summarized and stratified by sex (male and female), age group (<55 years, 
55–64 years, 65–75 years, and >75 years) and according to left ventricular ejection fraction (LVEF) 
(≤45% and >45%). Continuous variables are presented as the mean ± standard deviation (SD), median or 
interquartile range. For comparisons of continuous variables, the t‐test or Mann–Whitney U‐test was 
used. Categorical variables are presented as percentages and statistical analyses were performed using 
chi‐squared or Fisher's exact tests for counts of less than 5. For group comparisons, the non‐parametric 











At 1‐year follow‐up, the prescription of GDMT [ACEIs/angiotensin receptor blockers (ARBs), BBs, 
mineralocorticoid receptor antagonists (MRAs)], as well as all‐cause mortality and all‐cause 
hospitalization were assessed. For visual presentation, Kaplan–Meier curves for all‐cause mortality and 
all‐cause hospitalization stratified by sex, age and LVEF category (≤45% and >45%) were constructed. 
Log‐rank tests were used to compare survival distributions. In patients with LVEF ≤45%, multivariable 
logistic regression models stratified by age and sex were used to assess the associations between predictor 
variables and GDMT prescription. For all‐cause mortality at 1‐year follow‐up, a stratified Cox model was 
used. In both cases, a stepwise procedure was performed, using a P‐value of <0.05 to allow entry to the 
model and a P‐value <0.05 to remain in the updated model. No interaction was tested. A two‐sided P‐
value <0.05 was used as a cut‐off value to indicate differences of statistical significance. All analyses 
were performed in SAS Version 9.3 or higher (SAS Institute, Inc., Cary, NC, USA). 
Results 
Of the 16 354 patients enrolled in the ESC HF‐LT Registry between 2011 and 2016, 9428 outpatients 
(median age: 66 years; 28.5% women) with chronic HF were included in the present analysis. 
Baseline demographic and clinical characteristics 
The baseline characteristics of all patients and comparisons between sexes are presented in Table 1. In 
comparison to male patients, women with chronic HF were older (median age of women and men: 
69 years and 65 years, respectively), and had a lower body mass index (BMI), and higher mean systolic 
blood pressure (SBP) and heart rate (HR). Women also had higher mean LVEF compared to men 
(41.8 ± 15.0% and 35.3 ± 12.6%, respectively) and a higher prevalence of preserved LVEF >45%. Despite 
a higher mean LVEF, women more frequently presented with New York Heart Association (NYHA) class 
III or IV symptoms. Ischaemic heart disease (IHD), diabetes, peripheral artery disease (PAD), chronic 
obstructive pulmonary disease (COPD), sleep apnoea, renal dysfunction (all P < 0.001), a history of 
stroke (P = 0.005) and hepatic dysfunction (P = 0.001) were more frequent in men, in whom the 
prevalence of prior HF hospitalization was also higher than in women. Women suffered more often from 
aortic stenosis and depression. Both sexes had similar clinical signs of HF at presentation (Table 1). 
 
Baseline characteristics stratified by age group in both sexes are presented in online supplementary 
Tables S1 and S2. Female patients showed an age‐related increase in the prevalences of lower BMI, 
higher SBP, lower HR and higher mean LVEF. Older female patients more often presented with NYHA 
class III or IV symptoms, and a higher burden of comorbidities [e.g. valvular disease, IHD, atrial 
fibrillation (AF), diabetes, hypertension, PAD, stroke and renal dysfunction]. Similar age‐related 
characteristics were observed in men, but, in addition, pulmonary congestion and COPD became more 
prevalent in men with increasing age. 
Baseline heart failure treatment 
At baseline, high percentages of the total study population received ACEIs/ARBs or BBs (85.7% and 
88.7%, respectively). Overall, MRAs were prescribed to 58.8% of patients. Fewer women than men were 
treated with ACEIs/ARBs, BBs and MRAs (Table 1). Rates of prescription of these medications also 
decreased with patient age in both sexes (online supplementary Tables S1 and S2). In contrast, the 
proportions of patients prescribed diuretics, oral anticoagulants, nitrates and calcium channel blockers at 
baseline increased across the age categories (online supplementary Tables S1 and S2). 
Treatment for heart failure at 1‐year follow‐up 
At 1‐year follow‐up, there was a high persistence of GDMT utilization in the overall study population 
and the proportions of patients receiving ACEIs/ARBs, BBs and MRAs remained comparable with those 
at baseline (86.5%, 88.8% and 58.7%, respectively). However, there was an evident gap in rates of 
prescription of ACEIs/ARBs, BBs and MRAs in female compared to male patients (Table 2). Similarly, 
age‐related under‐prescription of the key HF medications persisted at 1‐year follow‐up in both sexes 
(online supplementary Tables S3 and S4). 
Table 1. Baseline demographic, clinical and treatment characteristics of female and male heart failure patients 
Characteristic   All patients  Female patients Male patients P‐value 
    (n = 9428)  (n = 2684)  (n = 6744) 
Age, years, median (IQR)  66.0 (57.0–75.0) 69.0 (59.0–78.0) 65.0 (56.0–74.0) <0.001 
BMI, kg/m2, mean ± SD  28.1 ± 5.1  27.9 ± 5.7  28.2 ± 4.9  <0.001 
SBP, mmHg, mean ± SD  124.4 ± 21.0 126.2 ± 22.2 123.7 ± 20.4 <0.001 
SBP ≤ 110 mmHg, n (%)  2848/9427 (30.2%) 779/2683 (29.0%) 2069/6744 (30.7%) 0.117 
HR, b.p.m., mean ± SD  73.1 ± 15.6 75.1 ± 16.6 72.3 ± 15.2 <0.001 
HR ≥70 b.p.m., n (%)   5278/9427 (56.0%) 1619/2683 (60.3%) 3659/6744 (54.3%) <0.001 
EF, %, mean ± SD   37.1 ± 13.6 41.8 ± 15.0 35.3 ± 12.6 <0.001 
EF >45%, n (%)   1938/8415 (23.0%) 850/2318 (36.7%) 1088/6097 (17.8%) <0.001 
NYHA class III or IV, n (%)  2454/9403 (26.1%) 778/2677 (29.1%) 1676/6726 (24.9%) <0.001 
Pulmonary or peripheral congestion, n (%) 2983/3982 (74.9%) 907/1194 (76.0%) 2076/2788 (74.5%) 0.317 
Third heart sound, n (%)  548/9108 (6.0%) 137/2589 (5.3%) 411/6519 (6.3%) 0.067 
Peripheral hypoperfusion/cold, n (%) 313/9123 (3.4%) 93/2594 (3.6%) 220/6529 (3.4%) 0.610 
Mitral regurgitation, n (%)  2419/9127 (26.5%) 714/2594 (27.5%) 1705/6533 (26.1%) 0.164 
Aortic stenosis, n (%)   373/9125 (4.1%) 140/2593 (5.4%) 233/6532 (3.6%) <0.001 
Prior HF hospitalization, n (%)  3963/9356 (42.4%) 1080/2670 (40.4%) 2883/6686 (43.1%) 0.018 
HF diagnosis >12 months, n (%)  4837/7808 (61.9%) 1368/2178 (62.8%) 3469/5630 (61.6%) 0.330 
Ischaemic aetiology, n (%)  4021/9372 (42.9%) 742/2668 (27.8%) 3279/6704 (48.9%) <0.001 
Atrial fibrillation, n (%)  3537/9427 (37.5%) 1028/2683 (38.3%) 2509/6744 (37.2%) 0.314 
Diabetes mellitus, n (%)  2940/9428 (31.2%) 762/2684 (28.4%) 2178/6744 (32.3%) <0.001 
PAD, n (%)   1105/9129 (12.1%) 233/2594 (9.0%) 872/6535 (13.3%) <0.001 
Hypertension, n (%)   5534/9412 (58.8%) 1570/2675 (58.7%) 3964/6737 (58.8%) 0.896 
COPD, n (%)   1322/9409 (14.1%) 232/2677 (8.7%) 1090/6732 (16.2%) <0.001 
Sleep apnoea, n (%)   459/8933 (5.1%) 61/2536 (2.4%) 398/6397 (6.2%) <0.001 
Prior stroke/TIA, n (%)  881/9419 (9.4%) 215/2679 (8.0%) 666/6740 (9.9%) 0.005 
Renal dysfunction, n (%)  1772/9419 (18.8%) 443/2683 (16.5%) 1329/6736 (19.7%) <0.001 
Hepatic dysfunction, n (%)  320/9138 (3.5%) 65/2597 (2.5%) 255/6541 (3.9%) 0.001 
Depression, n (%)   692/9387 (7.4%) 321/2675 (12.0%) 371/6712 (5.5%) <0.001 
Pacemaker, n (%)   545/9399 (5.8%) 203/2676 (7.6%) 342/6723 (5.1%) <0.001 
ACEIs/ARBs, n (%)   6285/7337 (85.7%) 1587/1968 (80.6%) 4698/5369 (87.5%) <0.001 
Beta‐blockers, n (%)   8357/9424 (88.7%) 2274/2682 (84.8%) 6083/6742 (90.2%) <0.001 
MRAs, n (%)   5542/9425 (58.8%) 1508/2683 (56.2%) 4034/6742 (59.8%) 0.001 
Diuretics, n (%)   7798/9424 (82.7%) 2255/2682 (84.1%) 5543/6742 (82.2%) 0.031 
Digitalis, n (%)   2149/9422 (22.8%) 632/2683 (23.6%) 1517/6739 (22.5%) 0.275 
Statins, n (%)   5690/9424 (60.4%) 1413/2683 (52.7%) 4277/6741 (63.4%) <0.001 
Antiplatelets, n (%)   4616/9424 (49.0%) 1094/2683 (40.8%) 3522/6741 (52.2%) <0.001 
Oral anticoagulants, n (%)  4004/9423 (42.5%) 1121/2683 (41.8%) 2883/6740 (42.8%) 0.379 
Amiodarone, n (%)   1282/9203 (13.9%) 290/2612 (11.1%) 992/6591 (15.1%) <0.001 
Ivabradine, n (%)   768/9147 (8.4%) 224/2598 (8.6%) 544/6549 (8.3%) 0.624 
Nitrates, n (%)   1770/9146 (19.4%) 472/2598 (18.2%) 1298/6548 (19.8%) 0.071 
Calcium channel blockers, n (%)  1043/9146 (11.4%) 314/2597 (12.1%) 729/6549 (11.1%) 0.193 
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic 
obstructive pulmonary disease; EF, ejection fraction; HF, heart failure; HR, heart rate; IQR, interquartile range; MRA, 
mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PAD, peripheral artery disease; SBP, systolic blood 
pressure; SD, standard deviation; TIA, transient ischaemic attack. 
Table 2. Management at 1‐year follow‐up in female vs. male patients with heart failure 
    All patients Female patients Male patients  P‐value 
    (n = 9428)  (n = 2684)  (n = 6744)  
ACEIs/ARBs, n (%)   6493/7509 (86.5%) 1766/2107 (83.8%) 4727/5402 (87.5%) <0.001 
Beta‐blockers, n (%)   6674/7515 (88.8%) 1800/2108 (85.4%) 4874/5407 (90.1%) <0.001 
MRAs, n (%)   4409/7516 (58.7%) 1183/2107 (56.1%) 3226/5409 (59.6%) 0.006 
Diuretics, n (%)   6080/7518 (80.9%) 1722/2109 (81.7%) 4358/5409 (80.6%) 0.284 
Digitalis, n (%)   1583/7517 (21.1%) 446/2108 (21.2%) 1137/5409 (21.0%) 0.896 
Statins, n (%)   4715/7517 (62.7%) 1167/2108 (55.4%) 3548/5409 (65.6%) <0.001 
Antiplatelets, n (%)   3581/7515 (47.7%) 846/2107 (40.2%) 2735/5408 (50.6%) <0.001 
Oral anticoagulants, n (%)  3263/7517 (43.4%) 877/2108 (41.6%) 2386/5409 (44.1%) 0.049 
Amiodarone, n (%)   1202/7517 (16.0%) 249/2108 (11.8%) 953/5409 (17.6%) <0.001 
Ivabradine, n (%)   751/7515 (10.0%) 211/2108 (10.0%) 540/5407 (10.0%) 0.977 
Nitrates, n (%)   1346/7330 (18.4%) 351/2056 (17.1%) 995/5274 (18.9%) 0.075 
Calcium channel blockers, n (%)  840/7517 (11.2%) 261/2108 (12.4%) 579/5409 (10.7%) 0.038 









Predictors of treatment at 1‐year follow‐up 
The analysis of GDMT predictors was restricted to patients with LVEF ≤45%, in whom this treatment 
has a proven outcome benefit. In the multivariable analysis, sex was not confirmed as an independent 
predictor of the use of ACEIs/ARBs, BBs or MRAs. Advanced age (>75 years) was a significant 
predictor of a lower use of GDMT compared to younger age categories. 
 
The odds of receiving ACEIs/ARBs increased with higher BMI and the absence of lower SBP 
(<110 mmHg). The odds of ACEI/ARB treatment were lower in patients with higher NYHA class (III or 
IV), prior HF hospitalization, and renal or hepatic dysfunction (Table 3). 
Table 3. Multivariable analysis of independent predictors of treatment in patients with left ventricular ejection fraction of ≤45% 
   Odds ratio (95% CI)a P‐value 
ACEI/ARB treatment   
Female patients  0.96 (0.77–1.21)  0.7401 
Age <55 years  1.93 (1.42–2.61)  <0.0001 
Age 55–64 years  1.98 (1.50–2.61)  <0.0001 
Age 65–75 years  1.36 (1.07–1.73)  0.0118 
BMI   1.06 (1.04–1.08)  <0.0001 
SBP ≤ 110 mmHg  0.63 (0.52–0.77)  <0.0001 
NYHA class III or IV  0.58 (0.48–0.71)  <0.0001 
Prior HF hospitalization 0.74 (0.62–0.90)  0.0019 
Hypertension  1.35 (1.10–1.65)  0.0035 
Renal dysfunction  0.32 (0.26–0.39)  <0.0001 
Hepatic dysfunction  0.52 (0.36–0.75)  0.0006 
BB treatment   
Female   0.81 (0.64–1.03)  0.0827 
Age <55 years  1.60 (1.16–2.21)  0.0038 
Age 55–64 years  1.93 (1.43–2.61)  <0.0001 
Age 65–75 years  1.45 (1.11–1.90)  0.0062 
NYHA class III or IV  0.64 (0.52–0.80)  <0.0001  
Prior HF diagnosis  1.45 (1.18–1.79)  0.0004 
COPD   0.51 (0.40–0.66)  <0.0001 
Depression  0.60 (0.43–0.83)  0.0021 
PM   0.55 (0.38–0.79)  0.0012 
MRA treatment   
Female   1.09 (0.95–1.24)  0.2098 
Age <55 years  2.03 (1.70–2.42)  <0.0001 
Age 55–64 years  1.92 (1.64–2.25)  <0.0001 
Age 65–75 years  1.57 (1.35–1.82)  <0.0001 
SBP ≤ 110 mmHg  1.55 (1.37–1.74)  <0.0001 
NYHA class III or IV  1.60 (1.41–1.83)  <0.0001 
Third heart sound  1.78 (1.39–2.28)  <0.0001 
Prior HF hospitalization 1.55 (1.39–1.73)  <0.0001 
Atrial fibrillation  1.26 (1.12–1.42)  0.0001 
Renal dysfunction  0.50 (0.43–0.57)  <0.0001 
ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta‐blocker; BMI, body mass index; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; MRA, mineralocorticoid receptor antagonist; 
NYHA, New York Heart Association; PM, pacemaker; SBP, systolic blood pressure. 
a Reference values are male for sex and age >75 years for age. 
Variables included in the Cox model: age classes, gender, BMI at baseline, SBP ≤110 mmHg, heart rate ≥70 b.p.m., NYHA class III 
or IV status, pulmonary or peripheral congestion, S3 gallop (third heart sound), peripheral hypoperfusion/cold, mitral regurgitation, 
aortic stenosis, prior HF hospitalization, HF diagnosis of >12 months, ischaemic aetiology, atrial fibrillation, diabetes mellitus, 
peripheral artery disease, hypertension treatment, COPD, sleep apnoea, prior stroke/transient ischaemic attack, renal dysfunction, 
hepatic dysfunction, depression, device therapy (PM). 
Prior HF diagnosis (vs. de novo HF) was associated with higher odds for BB prescription (Table 3). 
Conversely, the likelihood of BB prescription was lower in patients with higher NYHA class (III or IV), 
COPD, depression and the presence of a pacemaker. 
 
Mineralocorticoid receptor antagonists were more likely to be used in patients with lower SBP, higher 
NYHA class (III or IV), prior HF hospitalization, third heart sound and AF. Renal dysfunction was 
associated with a lower use of MRAs (Table 3). 
 
All‐cause mortality and all‐cause hospitalization at 1 year 
At follow‐up, 8.2% of patients had died. Cardiovascular death was the most common cause of 
mortality (52.0%) in both sexes, whereas non‐cardiovascular and unclassified deaths were recorded in 
23.0% and 25.0% of patients, respectively. Hospitalization for any cause occurred in 25.7% of patients 
and hospitalization for HF in 12.0% (Table 4). 
Table 4. Outcomes in female and male heart failure patients at 1 year 
   All patients Female patients Male patients P‐value 
   (n = 9428)  (n = 2684)  (n = 6744) 
All‐cause death, n (%) 757/9198 (8.2%) 186/2613 (7.1%) 571/6585 (8.7%) 0.015 
Causes of death 
CV death, n (%)  394/757 (52.0%) 102/186 (54.8%) 292/571 (51.1%)  
  Non‐CV death, n (%) 175/757 (23.1%) 38/186 (20.4%) 137/571 (24.0%) 0.565 
  Unknown, n (%)  188/757 (24.8%) 46/186 (24.7%) 142/571 (24.9%)  
All‐cause hospitalization, n (%) 2367/9198 (25.7%) 571/2613 (21.9%) 1796/6585 (27.3%) <0.001 
HF hospitalization, n (%) 1030/8357 (12.3%) 257/2364 (10.9%) 773/5993 (12.9%) 0.011 
CV, cardiovascular; HF, heart failure. 
 
Compared to men, women had lower rates of all‐cause mortality and all‐cause hospitalization, as well 
as a lower rate of HF hospitalization. Although mortality was lower in women, there were no sex‐related 
differences in causes of death (Table 4). 
 
Rates of all‐cause mortality, all‐cause hospitalization and HF hospitalization demonstrated significant 
increases with greater age in both sexes (online supplementary Table S5). 
 
Figures 1 and 2 present Kaplan–Meier survival curves for all‐cause death and all‐cause hospitalization 
stratified by sex and LVEF (≤45% and >45%). Online supplementary Figures S1 and S2 present similar 
data for the cohort stratified by age category and LVEF (≤45% and >45%). 
 
 





Figure 2. Kaplan–Meier product–limit survival estimates for all‐cause hospitalization by gender and ejection fraction (EF) 
subtype (%). 
Predictors of 1‐year all‐cause mortality 
The analysis of the predictors of 1‐year all‐cause mortality was restricted to patients with LVEF 
≤45%. In multivariable analysis, sex was not an independent predictor of mortality. The hazard ratios for 
death were significantly lower in patients of younger age, compared to patients aged >75 years. The 
likelihood of death was also lower with increasing BMI. The risk for mortality increased with lower SBP, 
NYHA class III or IV status, presence of pulmonary or peripheral congestion, aortic stenosis, PAD and 
renal dysfunction (Table 5). 
Table 5. Multivariable analysis of independent predictors of all‐cause death in patients with left ventricular ejection fraction ≤45% 
    Hazard ratio (95% CI)a P‐value 
Female    0.90 (0.68–1.18)  0.4333 
Age <55 years   0.48 (0.32–0.71)  0.0003 
Age 55–64 years   0.70 (0.52–0.96)  0.0260 
Age 65–75 years   0.65 (0.49–0.86)  0.0025 
BMI    0.96 (0.94–0.99)  0.0025 
SBP ≤110 mmHg   1.57 (1.25–1.98)  0.0001 
NYHA class III or IV status  1.98 (1.56–2.51)  <0.0001 
Pulmonary or peripheral congestion 2.15 (1.50–3.09)  <0.0001 
Aortic stenosis   1.58 (1.04–2.41)  0.0323 
PAD    1.40 (1.06–1.84)  0.0184 
Renal dysfunction   1.70 (1.34–2.16)  <0.0001 
BMI, body mass index; CI, confidence interval; HF, heart failure; NYHA, New York Heart Association; PAD, peripheral artery 
disease; SBP, systolic blood pressure. 
a Reference values are male for sex and age >75 years for age. 
Variables included in the Cox model: age classes, gender, BMI at baseline, SBP ≤110 mmHg, heart rate ≥70 b.p.m., NYHA class 
III/IV, pulmonary or peripheral congestion, S3 gallop (third heart sound), peripheral hypoperfusion/cold, mitral regurgitation, aortic 
stenosis, prior HF hospitalization, HF diagnosis of >12 months, ischaemic aetiology, atrial fibrillation, diabetes mellitus, PAD, 
hypertension treatment, chronic obstructive pulmonary disease, sleep apnoea, prior stroke/transient ischaemic attack, renal 
dysfunction, hepatic dysfunction, depression, device therapy (pacemaker). 
Discussion 
The present study provides important information on age‐ and sex‐related differences in the clinical 
presentation, management and outcomes of chronic HF in a large, multinational cohort of ambulatory 
patients included in the ESC HF‐LT Registry. 
Baseline demographic and clinical characteristics of patients 
The median age, 66 years, of the overall study population in the present registry was lower than the 
mean ages (>70 years) reported in most earlier registries of chronic HF
23-26
 and more closely 
corresponded to this patient characteristic in recent clinical trials in patients with HF with reduced 
ejection fraction (HFrEF).27 This provides important information on the clinical characteristics and 
management of a relatively younger HF patient population drawn from real‐world cardiology practice 
across Europe. The lower median age probably reflects the inclusion of patients treated by cardiologists in 
accordance with the registry protocol, rather than the more general patient population included in most 




This registry included a significantly higher proportion of male (71.5%) than female patients. The 
reasons for this male predominance remain unresolved. It may relate to several factors, such as women's 
or doctors' underestimation of cardiovascular symptoms in female patients, the difficulties faced by 
women in participating in clinical trials or registries, and female under‐representation caused by current 
study design, including the exclusion of outpatients with prevalent HFrEF. Other registries and clinical 
trials of HF patients have also documented a male predominance among the patients included.
23-30
 This 
discrepancy may be relevant in the applicability of evidence‐based therapies to both sexes. 
 
Compared to men, female patients were on average 4 years older and more symptomatic, as indicated 
by a greater proportion of NYHA class III or IV symptoms, despite similar clinical presentations and 
better LVEF. These results comply with the MAGGIC meta‐analysis of 31 studies including 41 949 
patients (13 897 women), which demonstrated that women with HF were on average 5 years older than 
men with HF (mean ± SD age: 70.5 ± 12.1 years and 65.6 ± 11.6 years, respectively). Further, previous 
data indicate a greater burden of HF symptoms in women and differences between the sexes in aetiology, 




Similarly to the present registry, the MAGGIC database has also suggested a lower prevalence of IHD 
(46.3% vs. 58.7%) and a higher prevalence of hypertension (49.9% vs. 40.0%) in women than in men.
28
 
Likewise, in a Norwegian cohort of HF patients, women with LVEF <50% had less frequent ischaemic 
HF aetiology than did men (57% and 63%, respectively).
23
 Type 2 diabetes mellitus (T2DM) in HF varies 
in prevalence from 20% to 40% and is less frequent in randomized trials than in registries, and sex‐related 
differences in T2DM are inconsistent. In the Chronic Heart Failure Analysis and Registry in Tohoku 
District‐2 (CHART‐2), T2DM was less prevalent in female than in male patients (31.7% and 36.4%, 
respectively).
9 
In contrast, the MAGGIC database reported a higher frequency of T2DM in female than in 
male patients (25.4% and 22.8%, respectively).
28
 The Norwegian cohort showed no difference in T2DM 
prevalence between the sexes.
23
 In the present registry, the prevalence of T2DM was ∼30%, and it was 
less frequently observed in females than in males (28% and 32%, respectively). 
 
Similarly to T2DM, higher prevalences of renal dysfunction have been reported in HF patients in 
registries than in clinical trials, in which severe renal dysfunction is generally an exclusion criterion. Sex‐
related heterogeneity in chronic kidney disease in HF has also been reported, with considerable 
discrepancies among studies. In the Olmsted cohort, the prevalence of chronic renal failure was lower in 
women than in men with HF, regardless of LVEF.
32
 Conversely, in the National HF Registry under the 
Spanish Society of Internal Medicine (RICA), more women than men had chronic renal failure (59.1% 
and 53.0%, respectively), and it was not associated with impaired survival.
26
 In the present registry, renal 
dysfunction was more often observed in men than in women (19.7% and 16.5%, respectively) and was 
associated with greater mortality. 
 
In the current registry, COPD was more frequent in male than in female patients, probably as a 
consequence of a greater burden of smoking among men or of underdiagnosis of COPD in women.
26, 33-35
 
In addition, and as expected, male patients more often suffered from sleep apnoea than did females.
36, 37 
The frequency of depression in HF in female patients was more than double than that in male patients 
(12.0% and 5.5%, respectively). Previous data, including a meta‐analysis of 27 studies of patients with 
HF, have shown similar findings.
38
 The underlying reasons are currently unknown. Several clinical, 
cultural and societal factors have been implicated and deserve further specific investigation because 





The majority of participants (77.0%) in the present registry had LVEF ≤45%. The predominance of 
reduced LVEF may suggest a selection bias that arises from the more severe clinical presentation of HF 
typically observed in the cardiology departments and specialized HF units that served as recruiting 
institutions for the ESC HF‐LT Registry. Compared to men, women had higher mean ± SD LVEF 
(35 ± 13% and 42 ± 15%, respectively) and a higher rate of LVEF >45%. This is consistent with previous 
reports and confirms a lesser propensity for HFrEF in women than in men.
25, 28, 42, 43
 
Baseline and follow‐up medical management 
Despite high GDMT uptake in the overall population, crude prescription rates of ACEIs/ARBs, BBs 
and MRAs were lower in women than in men. This may be related to the higher prevalence of HF with 
preserved LVEF in women, which discourages treatment in view of no real survival benefit. However, 
even in HF patients with preserved ejection fraction, the use of ACEIs/ARBs, BBs and MRAs is currently 
recommended for the treatment of associated comorbidities (i.e. hypertension, AF etc.). The present study 
also observed a decline in GDMT prescription rates with ageing in both sexes, and an increase in the use 
of diuretics, oral anticoagulants, amiodarone and other ancillary therapies, indicative of an age‐related 
greater burden of congestion and comorbidities. The proportion of patients receiving oral anticoagulants 
exceeded the proportion of patients with AF, suggesting that other indications or perhaps only 
significantly reduced LVEF influenced the decision to use anticoagulants. There was no improvement in 
sex‐ or age‐related discrepancies in the prescription of GDMT at 1‐year follow‐up. Sex was not an 
independent predictor of the prescription of GDMT (in a subset of patients with LVEF ≤45%). Older age 
(>75 years) was an independent predictor of a lower utilization of GDMT at 1‐year follow‐up. This 
implies that advanced age is an important obstacle to the implementation of GDMT and this may 
adversely impact on prognosis. 
 
These results are similar to those of the MAGGIC meta‐analysis, CHART 2 study and CHARM 
Program,
9, 27, 28
 although the overall proportion of patients receiving evidence‐based therapies has 
increased compared to those in the earlier reports. In IMPROVE, there was a trend towards the lower 
prescription of evidence‐based medications in the ageing population regardless of sex, and rates of use of 




Specifically, older age, higher NYHA class and impaired renal function have been repeatedly reported 
as predictors of MRA underuse. MRAs have been proven to be effective in elderly patients and in patients 
with moderate renal impairment (estimated glomerular filtration rate ≥30 mL/min/1.73 m2).
45
 More 
cautious MRA use is required in patients with high serum potassium levels, even when renal function is 
not significantly reduced, but this issue could be resolved with the use of potassium binders.
46
 High serum 
potassium can also be the reason for a reluctance to up‐titrate ACEIs/ARBs to optimal doses, but it does 
not adversely impact on the beneficial effects of ACEIs/ARBs.
47
 In addition, frailty has been identified as 
an obstacle to the use of GDMT, in particular MRAs, although their beneficial effects on outcomes 
appears to be unaffected by frailty.
48, 49 
Therefore, GDMT underuse cannot be justified by these clinical 
scenarios. 
  
Sex‐ and age‐related differences in outcomes 
Compared to male patients, females had lower crude rates of all‐cause mortality and all‐cause 
hospitalization, as well as a lower crude rate of HF hospitalization. Although mortality was lower in 
women, there were no sex‐related differences in causes of death. These results are in line with those of 
the CHARM trial and the MAGGIC meta‐analysis.27, 28 A recent analysis of patients with dilated 
cardiomyopathy demonstrated better survival in women compared to men, which was explained by less 
severe left ventricular dysfunction and a smaller scar burden.
50
 In addition, favourable outcomes were 
noticed in patients aged <60 years, whereas male patients aged >60 years demonstrated higher all‐cause 
mortality and a greater propensity for non‐sudden death compared to women.50 These findings are likely 
to reflect differences in characteristics and associated comorbidities between patients with dilated 
cardiomyopathy and those with chronic HF of any aetiology included in the current study. 
 
In the present study, rates of all‐cause mortality, all‐cause hospitalization and HF hospitalization 
significantly increased with advancing age in both sexes.
28, 51, 52
 Sex, however, was not an independent 
predictor of all‐cause mortality. 
Limitations 
There are several limitations to the present analysis. The study population consisted of outpatients 
managed mostly by cardiologists and hence does not completely reflect usual clinical practice. A further 
limitation refers to the lack of central validation and adjudication of diagnoses, LVEF measurements and 
causes of death. Some variables with prognostic importance, such as natriuretic peptide levels, were 
largely missing and therefore excluded from the analysis. The proportion of patients not using 
medications for reasons of contraindications or intolerance, and the proportion of patients deemed eligible 
for treatment but not receiving GDMT were not documented. At the time of analysis, the use of devices 
[cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators, CRT defibrillators] was 
not widespread in several of the participating countries, and conclusions regarding these treatment 
modalities could not be adequately inferred. Finally, patients were stratified by LVEFs of ≤45% and 
>45% (according to an analysis plan defined at the time of registry commencement). These limitations 
can serve as valuable reminders of how to design future research projects to more closely represent the 
real‐world population of HF patients. 
Conclusions 
The present study has demonstrated significant differences in the clinical characteristics and 
management of HF patients in relation to age and sex. There was a decline in GDMT prescription with 
advanced age in both sexes, suggestive of an underutilization of evidence‐based therapies, which may 
have adversely impacted prognosis. Sex was not independently associated with either GDMT prescription 
or outcomes. However, older age (>75 years) independently predicted a lower use of GDMT and a higher 
rate of all‐cause mortality. Although the reasons behind the disparities observed may be complex, it is 
important to raise awareness among physicians of the fact that persistence in obtaining the optimal 
management of patients with HF is of crucial importance in improving outcomes.
53
 Further research into 
the causes of undertreatment of HF in elderly patients may provide important insights that will facilitate 
the improvement of treatment options. 
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